Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/2/25 Pfizer (PFE) Disitamab Vedotin for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
6/2/25 Daiichi (4568) Enhertu for HER2+ Breast Cancer Subscribers Only Subscribers Only Subscribers Only
6/2/25 GSK (GSK) Jemperli for Ovarian Cancer Subscribers Only Subscribers Only Subscribers Only
6/2/25 Corcept Therapeutics (CORT) Relacorilant for Ovarian Cancer Subscribers Only Subscribers Only Subscribers Only
6/2/25 AstraZeneca (AZN) Tagrisso for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/12/2025 Subscribers Only Subscribers Only Trial Data - Other
05/20/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/22/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update